Date: 2013-07-30
Type of information: R&D agreement
Compound: therapeutic antibodies
Company: Antitope,wholly owned subsidiary of PolyTherics (UK) ChemomAb (Israel)
Therapeutic area: Inflammatory diseases
Type agreement: R&D
Action mechanism:
Disease: inflammatory diseases
Details: * On July 30, 2013, Antitope, a PolyTherics company, has announced a research agreement with ChemomAb for the generation of therapeutic antibodies for development as potential new treatments for inflammatory diseases. Under this agreement, Antitope will apply its Composite Human Antibody™ technology to generate fully humanised antibodies devoid of T cell epitopes with a consequent very low risk of clinical immunogenicity.
Antitope will humanise ChemomAb\'s first proprietary monoclonal antibody CM-101. This antibody has been developed to treat a series of immune-mediated disorders in humans. A pipeline of proprietary monoclonal antibodies is also currently tested in experimental models of orphan diseases.
Financial terms:
Latest news:
